Benzinga | Apr 19, 2021 10:45AM EDT

Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $50

Morgan Stanley maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $55 to $50.